- This topic contains 1 voice and has 0 replies.
September 11, 2017 at 2:49 pm #894565
Do you have Fibromyalgia?
There are a large number of people who have Fibromyalgia, a type of chronic pain that also includes fatigue and other bodily symptoms. There is currently no cure for Fibromyalgia and available treatments provide only modest benefits. The University of Washington’s Fibromyalgia Research Program is seeking participants for a study supported by a grant from the National Institutes of Health (NIH). This is a randomized study that involves a combination of different behavioral health and drug treatments with placebo controls. The project is attempting to evaluate different treatment combinations for people with Fibromyalgia, to see which ones work best and for whom.
Participation in the study will require 13 visits spaced over approximately 4 months with a follow-up visit 6 months after treatment has been completed. All visits will take place in the University District Building, 1107 Northeast 45th Street, Seattle, WA 98105. The building is conveniently located on several bus routes. Parking is available on request. Eligible participants will receive a comprehensive medical evaluation and a combination of pharmacological and behavioral health treatments. To participate in this study, individuals need to have received a diagnosis of Fibromyalgia by a health professional, currently have a primary healthcare provider, and be able to speak and understand verbal and written English. There are several additional eligibility requirements that can be discussed on the telephone with project staff if you are or someone you know is interested in learning more.
Participants may be paid up to $300 upon completion of the study. If you or someone you know has been diagnosed with Fibromyalgia and you or they would like to learn more about this study, please contact the Fibromyalgia Research Program at (206) 221-1737 or firstname.lastname@example.org (we cannot guarantee the confidentiality of any information sent by email).
- You must be logged in to reply to this topic.